Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

3.05USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$3.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
174,351
52-wk High
$66.00
52-wk Low
$2.90

Latest Key Developments (Source: Significant Developments)

Altimmune Says William Enright To Resign As President, CEO Of Co And Member Of Board
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Altimmune Inc ::ALTIMMUNE SAYS ON OCT 16 WILLIAM ENRIGHT NOTIFIED BOARD THAT HE INTENDS TO RESIGN AS PRESIDENT, CEO OF CO AND MEMBER OF BOARD - SEC FILING.ALTIMMUNE SAYS ENRIGHT STATED THAT HIS DECISION TO RESIGN INVOLVED A DISAGREEMENT OVER SCOPE OF HIS RESPONSIBILITIES AT CO.ALTIMMUNE INC - CO, ENRIGHT HAVE AGREED THAT ENRIGHT WILL REMAIN PRESIDENT, CEO UNTIL EARLIER OF APPOINTMENT OF HIS SUCCESSOR OR FEB 28, 2019.ALTIMMUNE INC - ENRIGHT WILL ALSO REMAIN ON BOARD UNTIL HIS RESIGNATION AS PRESIDENT AND CEO IS EFFECTIVE.ALTIMMUNE - ENRIGHT'S DECISION TO RESIGN IS NOT OTHERWISE RESULT OF ANY DISAGREEMENT ON ANY MATTERS RELATING TO CO'S OPERATIONS, POLICIES/PRACTICES.ALTIMMUNE INC - BOARD HAS BEGUN A PROCESS TO IDENTIFY ENRIGHT'S SUCCESSOR.  Full Article

Altimmune Announces $4.9 Mln Registered Direct Offering
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK.ALTIMMUNE INC - REGISTERED DIRECT OFFERING OF 286,633 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $17.02 PER SHARE.ALTIMMUNE INC - TO USE NET PROCEEDS FROM THIS OFFERING FOR CONTINUED ADVANCEMENT OF DEVELOPMENT ACTIVITIES FOR OUR CLINICAL-STAGE PRODUCT PIPELINE.  Full Article

Altimmune Announces Additional Positive Data From Its Phase 2A Study Of NasoVAX Intranasal Influenza Vaccine
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES ADDITIONAL POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE.ALTIMMUNE INC - DURABLE SERUM IMMUNE RESPONSE AT SIX MONTHS COMPARED TO OVER 50% DECLINE WITH FLUZONE.ALTIMMUNE - SIX-MONTH DATA DEMONSTRATES STATISTICALLY SUPERIOR MUCOSAL IMMUNE RESPONSE PROVIDING A FIRST LINE OF DEFENSE AGAINST INFECTION.ALTIMMUNE INC - SIX-MONTH DATA DEMONSTRATES CONTINUED CLEAN SAFETY PROFILE.  Full Article

Altimmune Reports Q2 Loss Per Share Of $0.34
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.34.Q2 REVENUE $2.4 MILLION VERSUS $3.0 MILLION.AT JUNE 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $4.8 MILLION.DURING QUARTER, COMPANY RECEIVED $4.0 MILLION IN CASH RELATED TO ITS FEDERAL TAX REFUND RECEIVABLE.  Full Article

Altimmune Files For Common Units Offering Of Up To $24 Mln
Monday, 30 Jul 2018 

July 30 (Reuters) - Altimmune Inc ::ALTIMMUNE INC FILES FOR COMMON UNITS OFFERING OF UP TO $24.0 MILLION - SEC FILING.  Full Article

Altimmune Restructures Financing Agreement With Majority Of The Remaining Series B Investors
Thursday, 12 Jul 2018 

July 12 (Reuters) - Altimmune Inc ::ALTIMMUNE RESTRUCTURES FINANCING AGREEMENT WITH MAJORITY OF THE REMAINING SERIES B INVESTORS.ALTIMMUNE INC - ENTERED AGREEMENTS WITH SUBSTANTIALLY ALL REMAINING INVESTORS IN SERIES B FINANCING TO RESTRUCTURE, TERMINATE PREVIOUS ARRANGEMENTS.ALTIMMUNE INC - APPROXIMATELY 97% OF SERIES B FINANCING HAS NOW BEEN RESTRUCTURED.ALTIMMUNE - INVESTORS TO RECEIVE COMMON SHARES AS REPAYMENT OF FINAL INSTALLMENT OF SERIES B PREFERRED STOCK & TO TERMINATE OUTSTANDING WARRANTS HELD BY THEM.ALTIMMUNE - SERIES B FINANCING INVESTORS INCLUDE NOVARTIS VENTURES, HEALTHCAP, TRUFFLE CAPITAL, FIDELIS CAPITAL AND BONAVENTURE CAPITAL.  Full Article

Altimmune Appoints Mitchel Sayare As Executive Chairman Of Board
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Altimmune Inc ::ALTIMMUNE APPOINTS MITCHEL SAYARE AS EXECUTIVE CHAIRMAN OF THE BOARD, AND ADDS JOSÉ OCHOA TO ITS LEADERSHIP TEAM AS CHIEF BUSINESS OFFICER.ALTIMMUNE INC - APPOINTED MITCHEL SAYARE, PH.D., AS EXECUTIVE CHAIRMAN OF BOARD, EFFECTIVE IMMEDIATELY.  Full Article

Altimmune Restructures Financing Agreement
Friday, 22 Jun 2018 

June 22 (Reuters) - Altimmune Inc ::ALTIMMUNE RESTRUCTURES FINANCING AGREEMENT.ALTIMMUNE RESTRUCTURES FINANCING AGREEMENT.ALTIMMUNE - ENTERED AGREEMENT WITH LEAD INVESTOR AND ONE OTHER INVESTOR IN ITS SERIES B FINANCING TO RESTRUCTURE AND TERMINATE PREVIOUS ARRANGEMENTS.ALTIMMUNE-2 INVESTORS WHO HELD ABOUT 68% SHARES OF SERIES B PREFERRED STOCK, ASSOCIATED WARRANTS, TO GET CASH INSTEAD OF SHARES AS REPAYMENT.ALTIMMUNE INC - ADDITIONALLY, INVESTORS WILL RECEIVE A COMBINATION OF CASH AND COMMON STOCK TO TERMINATE ALL OUTSTANDING WARRANTS HELD BY THEM.  Full Article

Altimmune Q1 Loss Per Share $0.25
Tuesday, 15 May 2018 

May 15 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.25.Q1 REVENUE $2.7 MILLION VERSUS $300,000.Q1 ADJUSTED LOSS PER SHARE $0.23.  Full Article

Altimmune Says Elizabeth Czerepak Resigned From Her Position As Chief Financial Officer
Thursday, 10 May 2018 

May 10 (Reuters) - Altimmune Inc ::ALTIMMUNE INC - ON MAY 8 ELIZABETH CZEREPAK RESIGNED FROM HER POSITION AS CHIEF FINANCIAL OFFICER.ALTIMMUNE INC - COMMENCED A SEARCH FOR CZEREPAK'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER.  Full Article